ELB245

· elbion AG

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for ELB245, covering 2007-08-08 to 2007-08-08. Get the full timeline:

Most recent: Clinical Trial Update: ELB245 for 12 Weeks Versus 4mg Tolterodine in Patients With Incontinent Overactive Bladder (OAB) [Phase 2]